Market Trends of Pigmented Lesion Treatment Industry
Lasers and Energy-based Devices are Expected to Witness Significant Growth
Laser and energy-based devices are gaining traction, driven by their advantages, patient preferences, and the introduction of new products by market players.
An article in Statpearls, updated in July 2024, highlighted that laser devices, known for their minimally invasive nature and high efficacy, are becoming the go-to therapeutic choice for patients with pigmented lesions. Such findings, showcasing the benefits of these devices, are pivotal in boosting their adoption rates and subsequently fueling market growth.
The prevalence of pigmented lesions underscores the demand for treatment devices. A study published in the Journal of Stomatology and Oral and Maxillofacial Surgery in September 2022 revealed that 20.8% of the population had oral pigmentation. Notably, the study emphasized a higher prevalence of oral pigmentation among male smokers and those exposed to cigarette smoke, further underscoring the necessity for laser and energy-based devices.
Global regulatory approvals play a significant role in the market's expansion. For instance, in June 2022, Cynosure unveiled the PicoSure Pro device in the US. This device, featuring a 755 nm picosecond laser, was among the first of its kind to receive FDA clearance. The PicoSure Pro stands out for its unique energy delivery. It operates in a trillionth of a second and relies on pressure, rather than heat, for safe and effective pigmentation treatments and skin revitalization across all skin types.
Given the rising importance of energy-based devices in treating pigmented lesions and the surge in new product launches, this segment is poised for robust growth in the coming years.
North America is Expected to Dominate the Market Over the Forecast Period
North America leads the global pigmented lesions treatment market, driven by a surge in pigmentation disorders. The region's robust healthcare infrastructure, coupled with the presence of key market players, ensures effective treatment options.
Additionally, the initiatives taken for the screening of pigmented lesions and approvals from regulatory authorities boost market growth in the region.
Regulatory approvals play a pivotal role in shaping the market landscape. For instance, in March 2023, Candela Corporation garnered clearances from both the US FDA and Health Canada for its PicoWay laser system, which was expanded to treat even the challenging melasma condition. Such approvals introduce new products and fuel market growth in the US and Canada.
Regional initiatives focusing on pigmented lesion screenings enhance disease awareness and underline the necessity for treatments. For example, in April 2023, MedX Health Corp. signed an MoU with PharmaChoice Canada. This collaboration aimed to roll out MedX’s DermSecure Screening Platform across all PharmaChoice pharmacies, enabling swift dermatological assessments for pigmented lesions, moles, and other skin conditions.
Thus, factors such as heightened screenings, product approvals, and the establishment of dermatological clinics are driving the market’s growth in the region.
